We are dedicated to developing life changing medicines
N. Scott Fine
Chief Executive Officer
N. Scott Fine has been a Director of the Company since February 2014 and became our Chief Executive Officer on September 14, 2015. From 2004 until 2014, he was a principal at Scarsdale Equities, an investment banking firm located in New York City. Mr. Fine has been involved in investment banking for over 35 years, working on a multitude of debt and equity financings, buy and sell side M&A, strategic advisory work and corporate restructurings. Much of his time has been focused on transactions in the healthcare and consumer products area. Mr. Fine has led global transactions in healthcare, including medical devices, generic pharmaceuticals, and genetics. He also worked with The Tempo Group of Jakarta, Indonesia.
Mr. Fine was Chairman of the Board of The Global Virus Network (GVN), and he also was the lead investment banker on the initial public offering of Green Mountain Coffee Roasters, Inc. and Central European Distribution Corporation (“CEDC”), a multi-billion-dollar alcohol company. Mr. Fine continued his involvement with CEDC serving as a director from 1996 until 2014, during which time he led the CEDC Board in its successful efforts in 2013 to restructure the company through a pre-packaged Chapter 11 process whereby CEDC was acquired by the Russian Standard alcohol group.
Recently, Mr. Fine served as Vice Chairman and Chairman of the Restructuring Committee of Pacific Drilling from 2017 to 2018 where he successfully led the independent directors to a successful reorganization. He also served as sole director of Better Place Inc. from 2013 until 2015. In his role there, Mr. Fine successfully managed the global wind down of the company in a timely and efficient manner which was approved by both the Delaware and Israeli Courts.
Mr. Fine currently serves on the board of directors of Kenon Holdings Ltd. (NYSE: KEN). Mr. Fine also devotes time to several non-profit organizations, including through his service on the Board of Trustees for the IWM American Air Museum in Britain. Mr. Fine has been a guest lecturer at Ohio State University’s Moritz School of Law at Fordham University Law School.
Sharon H. Hrynkow, PhD
Chief Scientific Officer, Senior Vice President of Medical Affairs
Dr. Hrynkow joined the Company in September 2015. Prior to joining Cyclo Therapeutics, Dr. Hrynkow served in a range of leadership roles in global health at the National Institutes of Health (NIH), including as Deputy Director and Acting Director of the Fogarty International Center, Associate Director of the National Institute on Environmental Health Sciences, and Senior Advisor to the NIH Deputy Director. She also made seminal contributions in the fight against HIV/AIDS during her early federal service at the Department of State. In 2012, Dr. Hrynkow became the inaugural President of the Global Virus Network, a non-profit organization working to combat pandemic viral disease.
A developmental neuroscientist by training, Dr. Hrynkow has worked passionately for decades to advance science for the benefit of society, to now include her work at Cyclo Therapeutics to bring Trappsol® Cyclo™ to market approval for the benefit of patients suffering from Niemann-Pick Disease type C and Alzheimer’s Disease. She is frequently asked to serve on national and international advisory committees, and has served on the President’s Council of Advisors for Science and Technology, American Association for the Advancement of Science Committee on Science, Engineering and Public Policy (also as Chair) and the U.S. National Academies of Science, Engineering and Medicine’s Division of Earth and Life Sciences advisory committee. She has been recognized for her contributions to global health and global science through prestigious awards, including with the US President’s Merit Award for Senior Executives, the Order of Merit from the King of Norway, and as an elected Fellow of the American Association for the Advancement of Science and as an elected member of the Council on Foreign Relations.
Jeffrey L. Tate, PhD
Director, Chief Operating Officer and Chief Quality Officer
Dr. Tate is a seasoned executive with more than 30 years of operations experience in the biotechnology, pharmaceutical and nutritional supplements industries including: branded generic drugs, intellectual property strategy, product development, and cGMP manufacturing. He is intimately familiar with food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, experienced in implementation of all aspects of regulatory compliance and in successfully communicating with regulatory agency representatives.
Dr. Tate has successfully established compliant regulated manufacturing operations and integrated regulatory compliance programs resulting in timely, cost effective corporate-wide compliance, meeting regulatory agency requirements and customer expectations. He closely monitors developments in U.S. and international regulations to maintain compliance and identify regulatory and intellectual property strategies for new products and markets. He holds patents and trademarks in material processing and food formulation.
Chief Regulatory Officer, Senior Vice President for Business Development
Mike Lisjak is the Company’s Chief Regulatory Officer and Senior Vice President for Business Development at Cyclo Therapeutics, Inc. He brings 20+ years of Regulatory Strategy and Operations expertise within the biopharmaceutical and consulting industries for multiple therapeutic areas including cardiovascular, metabolic, neuroscience and pain and inflammation and rare disease.
Prior to joining Cyclo Therapeutics, Inc., Mr. Lisjak was the Director of Global Regulatory Affairs at Sanofi leading the Endocrinology and Neuromuscular Rare Disease Area, which then led to a new role as the Head of Global Regulatory Affairs for Established Products and Global Health. Proceeding Sanofi, Mike served as the Global Regulatory Services Lead for Accenture’s Life Sciences group accountable for the growth and strategic oversight for Accenture’s global regulatory offerings, capabilities and go-to-market strategy. Before Accenture, he held multiple leadership roles at Pfizer and Wyeth with responsibility for developing, maintaining and directing global regulatory strategies and resources in the provision of regulatory guidance and deliverables as well as to ensure optimal regulatory interactions with global/regional Health Authorities. Additionally, Mike supported and delivered formal due diligence assessments for priority business development activities.
He holds a Bachelor of Science degree from Rochester Institute of Technology in biology.
Joshua M. Fine
Chief Financial Officer
Mr. Fine was appointed our Chief Financial officer in June 2019 and brings more than 15 years of operational, investment banking and investing experience in Pharmaceutical and Biotechnology sectors. Josh brings to Cyclo financial expertise and an in-depth understanding of public company accounting.
Mr. Fine also brings significant experience in mergers and acquisitions, business development and strategy development. Josh served as Senior Vice President of Finance and Operations at Icagen, where as part of the management team he worked on two transformational acquisitions. After acquiring assets and talent out of Sanofi and Pfizer, Josh worked to transition both operating teams into financial and operational alignment. While at Icagen, Josh worked closely with the CEO to successfully negotiate and sign multiple licensing deals with Roche, Sanofi, and the Cystic Fibrosis Foundation. Additionally, Josh was part of the team that led to the strategic sale of Icagen to Ligand in April of 2020.
Prior to joining Icagen Mr. Fine was an investment banking professional focused in the Life Science and Healthcare sectors. In this role Josh was a part of or led, financings, strategic partnerships, mergers and acquisitions and advisory work.
Gerald F. Cox, MD, PhD
Acting Chief Medical Officer
Dr. Cox is the founder of Gerald Cox Rare Care Consulting, LLC, where since 2018 he has been providing expert advice to small companies in all phases of clinical development for investigational rare disease drugs. From 2016-2018, Dr. Cox was the Chief Medical Officer of Editas Medicine, where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, including the first approved IND for a CRISPR-based medicine to be delivered in vivo that is designed to treat a genetic form of blindness called Leber congenital amaurosis type 10. Prior to Editas Medicine, Dr. Cox held increasingly senior roles at Genzyme (now Sanofi Genzyme) for over 15 years, advancing to Vice President of Rare Disease Clinical Development. While at Genzyme, he played an instrumental role in the global development and approval of treatments for several lysosomal storage disorders, including the enzyme replacement therapies Aldurazyme® (laronidase) for Mucopolysaccharidosis type I in 2003, Elaprase® (idursulfase) for Mucopolysaccharidosis type II in Japan and the Asia Pacific region in 2007, and Cerezyme® (imiglucerase) for a label expansion in Gaucher disease type 3 in Australia and China in 2016, as well as the substrate reduction therapy Cerdelga® (eliglustat) for Gaucher disease type 1 in 2014. He also led the early clinical development of the enzyme replacement therapies Myozyme® (alglucosidase alfa) for infantile Pompe disease, which was approved in 2006, and olipudase alfa for Niemann-Pick disease type B, which recently completed a successful Phase 3 study. Dr. Cox has been affiliated with Boston Children’s Hospital during his entire career, where he is a Part-time Staff Physician in Genetics. He is also an Instructor in Pediatrics at Harvard Medical School.
Dr. Cox received his MD and PhD from the University of California at San Diego and his B.A. from Harvard College. He completed an internship and residency in pediatrics followed by clinical and post-doctoral research fellowships in genetics at Boston Children’s Hospital and was Director of the Medical Genomics Mapping Facility. Dr. Cox is board-certified by the American College of Medical Genetics and Genomics in Clinical, Biochemical, and Molecular Genetics, and he was board-certified by the American Academy of Pediatrics in the past. He serves on the Board of Directors for the National Tay-Sachs and Allied Diseases organization.
Acting Chief Commercial Officer
Mr. Belden began his career as an employee in Genentech’s SSF Commercial organization, where he spent 16 years launching products/indications across multiple therapeutic areas, including the launch of their BioOncology franchise and moving to increasing roles of responsibility, ultimately as Director of Hematology Sales. Mr. Belden is the Founder, President & CEO of Bridge Consulting LLC, where he has worked with over 60 emerging biotech companies over the past 17 years. In addition to providing commercial assessments for companies ranging from preclinical to Phase 2, he has provided critical commercial leadership to Phase 3 emerging biotech companies as an interim Chief Commercial Officer (iCCO). Mr. Belden currently serves as the iCCO at three Phase 3 companies. He also serves as the Commercial Expert for the California Life Sciences Institute’s (CLSI) FAST program.
Lori McKenna Gorski
Global Head of Patient Advocacy
Lori is a dedicated biotechnology professional with more than two decades of communications and patient advocacy experience, focused upon the unique and urgent needs of rare disease communities. Lori began her career at public relations agency Brodeur Worldwide and eventually moved to an in-house role at Thermo Fisher Scientific, where she oversaw all communications activities for 12 divisions worldwide, financial media relations, and executive communications. Lori also spent eight years as Director of Communications at Sanofi Genzyme where she led global communications for Rare Diseases. She was the main corporate spokesperson for inquiries into pipeline and clinical development programs, the price and value of commercialized orphan disease therapies, disease awareness initiatives and crisis issues. Lori was also positioned on the front lines of the largest crisis in the biotechnology company’s history as spokesperson for the shutdown of the company’s biological manufacturing facility that produced therapies used to treat two rare and serious diseases. Lori partnered with Genzyme’s Patient Advocacy function to ensure consistent messaging throughout resulting and long-term global product shortages, to be sure the perspectives of the patient community were represented, and she received the Vice President’s Award for this work. Eventually, Lori transitioned into a role in Global Patient Advocacy and initiated programs to support disease awareness, provide caregiver support, communicate clinical program updates and ensure compliant, two-way communication between Genzyme and patient communities. After two years at Radius Health where she was Senior Director of Communications and Advocacy for larger disease states, in 2017 Lori began her own consulting business devoted to supporting rare disease communities. A graduate of Boston College, Lori is a hands-on mom of two boys and is an active volunteer in her community. She also serves on the Board of a nonprofit organization called Our Odyssey. Our Odyssey connects young adults impacted by a rare or chronic condition with social and emotional support in the hope of improving their quality of life.
Trappsol® Cyclo™ is not currently approved for any indication.
Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.